While early, the results indicate drugs known as ITK inhibitors have the potential to match or surpass the efficacy observed with the injectable biologic Dupixent.

Corvus Pharmaceuticals soars on promising Phase 1 data for soquelitinib. But CRVS shares may not be able to sustain today's ...

Explore the most influential drug approvals of 2025, highlighting FDA-cleared therapies that impact public health and clinical care.

Approval based on global phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function compared to placebo (by 4.68% to 5.32%) ...

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Kymera Therapeutics reported on Monday that, for the second time this year, it has ...

The first known lawsuit has now been filed against the makers of Dupixent (dupilumab), alleging that the popular eczema and asthma drug caused or accelerated a deadly form of lymphoma. Filed in ...

When you start a medication like Dupixent (dupilumab), you expect relief from eczema or asthma, not the devastation of a cancer diagnosis. Yet growing medical evidence shows that some patients ...

A man with asthma, an Asian man at home sitting on the couch breathing in an inhaler An anti-inflammation injectable can help asthma patients with airways clogged by mucus The number of patients with ...

WEDNESDAY, Oct. 29, 2025 (HealthDay News) — An anti-inflammation injectable drug can reduce mucus buildup and improve breathing among asthma patients, a new clinical trial says. The drug dupilumab ...